Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Beclometasone (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Sponsors Teva Branded Pharmaceutical Products R&D
- 01 May 2019 Results of a post-hoc analysis assessing the relationship between spirometry values measured by clinic-based and handheld spirometers, published in the Respiratory Medicine
- 05 Mar 2018 Results (n=425) of analysis assessing effect of Beclomethasone Dipropionate on patient reported outcomes and quality of life presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 05 Mar 2018 Results of post hoc analysis (n=425) evaluating improvement of lung function with beclomethasone dipropionate (BDP) via a new, breath-actuated inhaler presented at the 2018 Annual Meeting of the American Academy of Allergy, Asthma and Immunology